Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial
Abstract The antiangiogenic agent apatinib has been shown to clinically improve responses to immune checkpoint inhibitors in several cancer types. Patients with N3 nasopharyngeal carcinoma have a high risk of distant metastasis, however, if the addition of immunotherapy to standard treatment could i...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Portfolio
2024-02-01
|
| シリーズ: | Nature Communications |
| オンライン･アクセス: | https://doi.org/10.1038/s41467-024-45126-0 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|